Presatovir Explained

Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus.^{[1] [2]} It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials.^{[3] [4]}

See also

• Palivizumab
• Lumicitabine
• Ziresovir

Notes and References

1. Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, Hui H, Zhang L, Siegel D, Yang H, Saunders O, Boojamra C, Lee G, Samuel D, Babaoglu K, Carey A, Gilbert BE, Piedra PA, Strickley R, Iwata Q, Hayes J, Stray K, Kinkade A, Theodore D, Jordan R, Desai M, Cihlar T . 6 . Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study . Journal of Medicinal Chemistry . 58 . 4 . 1630–1643 . February 2015 . 25574686 . 10.1021/jm5017768 .
2. Yamaguchi-Sasaki T, Tamura Y, Ogata Y, Kawaguchi T, Kurosaka J, Sugaya Y, Iwakiri K, Busujima T, Takahashi R, Ueda-Yonemoto N, Tanigawa E, Abe-Kumasaka T, Sugiyama H, Kanuma K . 6 . Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors . Chemical & Pharmaceutical Bulletin . 68 . 4 . 345–362 . 2020 . 32238652 . 10.1248/cpb.c19-00895 . 214769862 . free .
3. Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, Bergeron A, Shoham S, Ljungman P, Waghmare A, Blanchard E, Kim YJ, McKevitt M, Porter DP, Jordan R, Guo Y, German P, Boeckh M, Watkins TR, Chien JW, Dadwal SS . 6 . A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract . Clinical Infectious Diseases . December 2019 . 31915807 . 10.1093/cid/ciz1167 . free . 7108198 .
4. Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, Miller M, Cihlar T, DeVincenzo J, Chien JW, Jordan R . 6 . Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus . The Journal of Infectious Diseases . January 2020 . 31971597 . 10.1093/infdis/jiaa028 .